NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

April 14, 2021

Study Completion Date

April 14, 2021

Conditions

Cluster Headache

Interventions

DRUG

C213 Microneedle System

The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.

DRUG

Placebo

The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.

Trial Locations (12)

14226

Dent Neuro Institute, Buffalo, Amherst

19107

Jefferson Headache Center, Philadelphia

22101

Medstar Georgetown University Hospital at McLean, McLean

30328

Atlanta Headache Specialists, Atlanta

75390

University of Texas Southwestern Medical Center- Neurology Clinic, Dallas

89113

Nevada Headache Institute, Las Vegas

90033

Keck Medicine of USC, Los Angeles

90404

California Medical Clinic for Headache, Santa Monica

94304

Stanford University, Palo Alto

06905

KI Health Partners LLC DBA New England Institute for Clinical Research, Stamford

01605

New England Regional Headache Center, Inc., Worcester

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors

lead

Zosano Pharma Corporation

INDUSTRY